US Pharma MarketingThe post ESMO26: Lunit SCOPE studies highlight AI-based pathology benefit appeared first on Medical Device Network.
ESMO26: Lunit SCOPE studies highlight AI-based pathology benefit
SCOPE was applied to a variety of studies and was applied towards varying cancer types. SCOPE was applied to a variety of studies and was applied towards varying cancer types. ESMO 2026 is taking place in Madrid, Spain between 23-27 October. Credit: frank60/Shutterstock.com Data from five studies involving Lunit’s SCOPE platform have demonstrated how artificial intelligence (AI)-based quantitative pathology can support research across different cancer types, further reinforcing the technology’s growing role in the field. Results from the studies are being presented at the 2026 European Society for Medical Oncology (ESMO) congress, held in Madrid from 23-27 October. Combine business…
SCOPE was applied to a variety of studies and was applied towards varying cancer types.
Source: Medical Device Network